Trading / Browse Companies / Mammoth Biosciences Stock

Mammoth Biosciences Stock

mammoth.bioHealthcareFounded: 2017Funding to Date: $257.38MM

Mammoth Biosciences is a biotechnology company that, through the discovery and development of novel CRISPR systems, the is enabling the full potential of its platform to improve lives by reading and writing the code of life.

Buy or sell Mammoth Biosciences stockLearn more about Mammoth Biosciences IPO
Register for Details

For more details on financing and valuation for Mammoth Biosciences, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for Mammoth Biosciences.

Register Today

Mammoth Biosciences investors also invested in these private companies

Mayfield Fund
Decheng Capital
NFX
Redmile Group
Foresite Capital

Team

Management Team

Ted Tisch
Chief Operating Officer
Trevor Martin Ph.D
Co-Founder & Chief Executive Officer
Lucas Harrington
Co-Founder & Chief Scientific Officer
Jennifer Doudna Ph.D
Co-Founder & Chairman of Scientific Advisory Board
Janice Chen Ph.D
Co-Founder & Chief Technology Officer
Peter Nell Ph.D
Chief Business Officer & Head of Therapeutics

Board Members

Jennifer Doudna Ph.D
Mammoth Biosciences
Ursheet Parikh
Mayfield Fund

Other companies like Mammoth Biosciences in the Healthcare sector

Neuralink
Sector
Healthcare
Last Round Est. Valuation
$2.15B
Altos Labs
Sector
Healthcare
Last Round Est. Valuation
$3.67B
Grail
Sector
Healthcare
Last Round Est. Valuation
$4.26B
Headspace
Sector
Healthcare
Last Round Est. Valuation
$317.32MM
OURA
Sector
Healthcare
 
 
GoForward
Sector
Healthcare
Last Round Est. Valuation
$1.59B
Biosplice Therapeutics
Sector
Healthcare
 
 
NowRx
Sector
Healthcare
Last Round Est. Valuation
$334.19MM
Cytonics
Sector
Healthcare
 
 

News

Crunchbase 09/09/2021
CRISPR biotech company Mammoth Biosciences gains unicorn status
San Francisco-based Mammoth Biosciences has closed on a $150 million Series D led by Redmile Group, which now values the CRISPR biotech company at $1 billion, making it a new addition to the Crunchbase Unicorn Board.
Techcrunch 07/31/2020
Mammoth Biosciences’s CRISPR-based COVID-19 test receives NIH funding through RADx program – TechCrunch
CRISPR tech startup Mammoth Biosciences is among the companies that revealed backing from the National Institutes of Health (NIH) Rapid Acceleration of Diagnostics (RADx) program on Friday. Mammoth received a contract to scale up its CRISPR-based SARS-CoV-2 diagnostic test in order to help address …
Techcrunch 05/20/2020
Mammoth Biosciences partners with GSK to develop handheld CRISPR-based COVID-19 test – TechCrunch
California-based Mammoth Biosciences has signed a powerful partner for its development of a CRISPR-based test for COVID-19, which would aim to delivery accurate, fast results using a handheld, disposable testing platform. Mammoth Biosciences will be using its DETECTR platform to develop the test, w…

Trending Companies

Frequently Asked Questions